Frequently Asked Questions

Unlike mRNA technologies, small molecule therapeutics are safer, less costly to produce, less costly to administer, and in the event of any potential side effects can be stopped immediately.  

Current pharmaceutical development methodologies take decades and billions of dollars in R&D expenditures to bring a new drug to market.  Those development costs must be recouped in a very limited amount of time during which a successful product has patent protection.  The existing process is very inefficient, has a very low overall rate of success, and drives the cost of lifesaving therapeutics to increasingly unsustainable levels.   Resmonix has developed proprietary design tools that can more efficiently identify and quantify how proteins interact, and how these interactions can be regulated in a more natural and understandable way.   This approach can cut years off the development cycle, while dramatically improving the success rate, and delivering better performance at much lower cost .    

Resmonix is working with a number of collaborative groups that are dedicated to doing transformative science with the vision of bringing lower cost therapeutics to those that need them most.  Contact us to discover how we might work together.